Research ArticleClinical Studies

Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan

TAKASHI ISHIKAWA, SATORU SHIMIZU, KIYOFUMI KATAYAMA, TAKASHI CHISHIMA, YOHEI HAMAGUCHI, TAKAKO DOI, MIKIKO TANABE, AKIO KASAHARA, NAOTAKA YAMAGUCHI, KAZUTAKA NARUI, IKUKO OHTA, CHIZURU MATSUMOTO, DAISUKE SHIMIZU, AYAKO KITO, TAKASHI SUDA, MASAAKI INABA, TARO ASAGA, NOBUYOSHI MOMIYAMA, YASUSHI ICHIKAWA, MASATAKA YOSHIMOTO, SATOSHI MORITA and HIROSHI SHIMADA
Anticancer Research May 2009, 29 (5) 1515-1520;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Schematic outline of the treatment protocol. AC at 60/600 mg/m2 or EC at 90/600 mg/m2 was given four times at three-week intervals, followed by weekly PAC (80 mg/m2) ×12, either as single weekly administration for 12 consecutive weeks (12 PAC) or four cycles of single weekly administration for three weeks followed by a one-week rest (3×4 PAC).

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Feasibility of AC/EC Followed by Weekly Paclitaxel in Node-positive Breast Cancer in Japan
TAKASHI ISHIKAWA, SATORU SHIMIZU, KIYOFUMI KATAYAMA, TAKASHI CHISHIMA, YOHEI HAMAGUCHI, TAKAKO DOI, MIKIKO TANABE, AKIO KASAHARA, NAOTAKA YAMAGUCHI, KAZUTAKA NARUI, IKUKO OHTA, CHIZURU MATSUMOTO, DAISUKE SHIMIZU, AYAKO KITO, TAKASHI SUDA, MASAAKI INABA, TARO ASAGA, NOBUYOSHI MOMIYAMA, YASUSHI ICHIKAWA, MASATAKA YOSHIMOTO, SATOSHI MORITA, HIROSHI SHIMADA
Anticancer Research May 2009, 29 (5) 1515-1520;
Twitter logo Facebook logo Mendeley logo

Jump to section